Litesitamet Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Lites Pharm Tech Co., Ltd.
MFDS item code 202200487 · Approved 2022.01.28
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise therapy to help control blood sugar in patients with type 2 diabetes. It can be used alone, especially in cases where patients have not been treated with blood sugar control medications previously. This drug is also used when blood sugar control is difficult with either metformin or sitagliptin monotherapy, or when replacing the combination of both drugs. In addition, if there is no effect with combination therapy of metformin and sulfonylurea, or metformin and thiazolidinedione, this medication can be used in combination to enhance therapeutic effects. It also improves blood sugar control when used together with insulin and metformin in cases where blood sugar control is insufficient. Therefore, it is used as an effective adjunct in various therapeutic situations for blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine). 2. Patients treated with metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral blood glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Receive This Medicine).
This medication contains sitagliptin and metformin, which require caution during use. First, this medication may cause allergic reactions, so if symptoms like hives, rash, or difficulty breathing occur, discontinue use immediately and consult a physician. There is a risk of acute pancreatitis, which is inflammation of the pancreas, so be vigilant for symptoms like abdominal pain, nausea, and vomiting, and stop taking the medication right away if suspected. Moreover, this medication should not be administered to patients with severe renal impairment, acute heart failure, or myocardial infarction, and it should be temporarily stopped before and after surgeries or examinations using radioactive iodine contrast agents. It is advisable not to use it in pregnant or breastfeeding women or in children and adolescents under 18 years of age, as safety has not been established. Regular monitoring of renal function is necessary while on this medication, especially for the elderly or patients with weakened kidney function. Additionally, this medication may cause hypoglycemia, so blood sugar levels should be carefully monitored in cases of irregular meal patterns, vigorous exercise, or when taken with other blood sugar-lowering agents. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided, and symptoms like malaise, muscle pain, respiratory distress, and abdominal pain should be reported to medical personnel immediately. During the course of this medication, rare side effects like severe joint pain or bullous pemphigoid may occur; if these symptoms occur, inform a doctor immediately. Finally, this medication may interact with various drugs, so if other medications are being taken, it is essential to consult with a physician or pharmacist, particularly when using drugs that might affect kidney function.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly closed container to prevent air or moisture from entering, and it is best stored at a temperature between 1°C and 30°C at room temperature. By doing so, the effectiveness of the medication can be maintained, and degradation can be prevented.
Brown oval film-coated tablet engraved with 751 on one side
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Lites Pharm Tech Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.